Ischemic Heart Disease | Ranolazine for Improving Symptoms of Palpitations

Ischemic Heart Disease research study

What is the primary objective of this study?

Patients with ischemic heart disease often report multiple symptoms, including angina and palpitations. Ranolazine has antiarrhythmic effects which are largely a result of the drug's effect on multiple ion channels. It remains unknown, however, whether the favorable effects of ranolazine on symptoms and arrhythmias are maintained over time. Aim of this study is to test the hypothesis that chronic treatment with ranolazine can improve the symptomatic status of patients with ischemic heart disease by reducing the occurrence of palpitations.

Who is eligible to participate?

Inclusion Criteria: - Symptoms of palpitations - Angiographically-proven coronary artery disease - Stable conditions - No recent acute coronary syndromes - Able to understand and willing to sign the informed consent form - Symptomatic patients (palpitation) with stable angina pectoris already on therapy with beta-blockers and/or calcium antagonists. Exclusion Criteria: - Women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours - Severe renal failure - Severe hepatic failure

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Ischemic Heart Disease

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Ranolazineos, pill, 750 mg, b.i.d., 30 days

Drug:Placeboos, pill, b.i.d., 30 days

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

RanolazinePatients will receive ranolazine 750 mg bid for 30 days

PlaceboPatients will receive placebo for 30 days

Study Status

Unknown status

Start Date: January 2014

Completed Date: December 2016

Phase: Phase 4

Type: Interventional


Primary Outcome: Occurrence of symptoms of palpitations

Secondary Outcome: Occurrence of arrhythmia in case of symptoms of palpitations

Study sponsors, principal investigator, and references

Principal Investigator: Francesco Pelliccia, MD

Lead Sponsor: University of Roma La Sapienza


More information:

Discuss Palpitations